Richard Moore is an Oncology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 351 publications with 15,065 citations (h-index 55); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Gynecologic Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
125 Lattimore Rd Ste 258
Rochester, NY 146204155
Telephone
585-442-8020Registry record last updated 28 Jun 2023.
Clinical trials
- Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
Sponsor: Fujirebio Diagnostics, Inc.
- Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
Sponsor: Women and Infants Hospital of Rhode Island
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fujirebio Diagnostics, IncorporatedProgram year20251 payment$14,765openpaymentsdata.cms.gov ↗
- Fujirebio Diagnostics, IncorporatedProgram year20241 payment$19,520openpaymentsdata.cms.gov ↗
- Fujirebio Diagnostics, IncorporatedProgram year20231 payment$16,456openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
55.9%Phenothiazine55.9%Prochlorperazine Maleate100%Part D≥33 patientsMetabolism & gastrointestinal
44.1%Serotonin-3 Receptor Antagonist44.1%Ondansetron Hcl59%Ondansetron Odt42%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Louis Constine, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Edward Messing, MD
University of Rochester Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”